Black Diamond Therapeutics (BDTX) Net Income towards Common Stockholders (2018 - 2021)
Historic Net Income towards Common Stockholders for Black Diamond Therapeutics (BDTX) over the last 4 years, with Q4 2021 value amounting to -$25.5 million.
- Black Diamond Therapeutics' Net Income towards Common Stockholders fell 1624.79% to -$25.5 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$93.8 million, marking a year-over-year decrease of 4160.46%. This contributed to the annual value of -$123.4 million for FY2021, which is 8832.29% down from last year.
- Latest data reveals that Black Diamond Therapeutics reported Net Income towards Common Stockholders of -$25.5 million as of Q4 2021, which was down 1624.79% from -$34.6 million recorded in Q3 2021.
- In the past 5 years, Black Diamond Therapeutics' Net Income towards Common Stockholders registered a high of -$3.0 million during Q4 2018, and its lowest value of -$34.6 million during Q3 2021.
- For the 4-year period, Black Diamond Therapeutics' Net Income towards Common Stockholders averaged around -$16.0 million, with its median value being -$13.5 million (2020).
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first crashed by 23530.33% in 2020, then plummeted by 1624.79% in 2021.
- Quarter analysis of 4 years shows Black Diamond Therapeutics' Net Income towards Common Stockholders stood at -$3.0 million in 2018, then crashed by 225.15% to -$9.9 million in 2019, then tumbled by 121.42% to -$21.9 million in 2020, then decreased by 16.25% to -$25.5 million in 2021.
- Its Net Income towards Common Stockholders was -$25.5 million in Q4 2021, compared to -$34.6 million in Q3 2021 and -$33.8 million in Q2 2021.